



Les traitements de demain

Shibeshih Belachew

C.H.U. de Liège


www.sepmydream.net

Journée médicale du 25 juin 2011


A la date du 24 juin 2011:

735 études cliniques en cours ou clôturées récemment et dont l'analyse est en cours ! <http://clinicaltrials.gov>

Objectifs des traitements




MSFC=Multiple Sclerosis Functional Composite; SF36-QOL=Short-Form 36 Quality of Life.




MSFC=Multiple Sclerosis Functional Composite; SF36-QOL=Short-Form 36 Quality of Life.

Choisir un traitement dans la SEP


Une part d'inconnu



Les options




Fingolimod et récepteurs à la sphingosine-1-P




Brinkmann and Lynch. *Curr Opin Immunol* 2002;14:569


Fingolimod et récepteurs à la sphingosine-1-P



Brinkmann and Lynch. *Curr Opin Immunol* 2002;14:569




Fingolimod
Mécanisme d'action




冬虫夏草
Cordyceps sinensis


- Agit en superagoniste des récepteurs à la spingosine-1-phosphate
- Induit l'internalisation des récepteurs S1P-R
- Prive les lymphocytes du signal nécessaire à leur sortie du thymus et des ganglions
- Augmente l'entrée des lymphocytes dans les ggl depuis le sang
- Les lymphocytes circulant et les **lymphocytes effecteurs** sont **séquestrés** dans les organes lymphoïdes (ggl, plaques de Peyer)




Brinkmann V et al. J. Biol. Chem. 2002;
Mandala S et al. Science 2002;
Brinkmann V et al. Am. J. Transplant. 2004;
Matloubian M et al. Nature 2004;
NEJM 2006;355(11):1088




Fingolimod et récepteurs à la sphingosine-1-P



冬虫夏草
Cordyceps sinensis







Etudes cliniques de phase III

Tysabri

Gilenya

AFFIRM

FREEDOMS



Polman CH et al. N Engl J Med. 2006;354:899-910; Havrdova E et al. Lancet Neurol. 2009;8:254-260; Munschauer F et al.ECTRIMS; September 2008, Montréal, Canada. Abstract #P474; Hutchinson et al. J Neurol. 2009 Mar;256(3):405-15. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.
Fingolimod EPAR Gilenya Assessment report. EMA/108602/2011

Etudes cliniques de phase III



Tysabri

Gilenya



Patients à haute activité (2 poussée/an et 2 Gd+)

AFFIRM





FREEDOMS



Polman CH et al. N Engl J Med. 2006;354:899-910; Havrdova E et al. Lancet Neurol. 2009;8:254-260; Munschauer F et al.ECTRIMS; September 2008, Montréal, Canada. Abstract #P474; Hutchinson et al. J Neurol. 2009 Mar;256(3):405-15. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.
Fingolimod EPAR Gilenya Assessment report. EMA/108602/2011




D'autres pistes ?



FAMPYRA (4AP-SR)

Walking speed (post-hoc analysis)

Responders: fampridine (36.7%), placebo (8.5%)



29/6/07


FAMPYRA (4AP-SR)

NEUROLOGY

Phase comparison trial of sustained-release fampridine in multiple sclerosis
A. D. Cochen, T. R. Brown, J. A. Cohen, L. D. Krupp, P. Schapiro, S. E. Schwid, R. Cohen, L. S. Sterns, A. P. Wright and for the Fampridine MSAT Study Group
Neurology 2007; 71:1144-1151. originally published online Jul 30, 2007
DOI: 10.1212/01.wnl.0000262213.00000




29/6/07



FAMPYRA (4AP-SR)


Walking speed (post-hoc analysis)

Responders: fampridine (36.7%), placebo (8.5%)



29/6/07

Choisir un traitement dans la SEP Une part d'inconnu



www.sepmydream.net